real-time news and commentary for investors
Tuesday, Sep 10
Mei Pharma acquires the rights to an investigational new blood cancer treatment from Pathway Therapeutics
- MEI Pharma (MEIP -0.3%) acquires the rights to PWT143, an investigational drug candidate from privately held Pathway Therapeutics.
- The drug was found during pre-clinical studies to be a potent and highly selective oral inhibitor of phosphatidylinositide 3-kinase delta, a molecular target that has been shown to play a critical role in the proliferation and survival of hematologic blood cancer cells.
- The purchase price was undisclosed, but the company did say it made an upfront payment with no future milestone or royalty obligations.
- The company expects to file an Investigational New Drug application with the FDA by the end of 2014.